"Revolutionary Nanovaccine-in-Hydrogel: A Game-Changer in Cancer Immunotherapy"
Scientists have developed a single-dose injectable nanovaccine-in-hydrogel (NvIH) for robust cancer immunotherapy. The nanovaccine, composed of immunostimulants and immune checkpoint blockade antibodies, is designed to remodel the tumor microenvironment, enhance antitumor immune responses, and elicit systemic antitumor immunity. In mouse models, the NvIH demonstrated significant inhibition and regression of large tumors, including orthotopic glioblastoma, with an abscopal effect on distant tumors. The nanovaccine holds promise for safe and effective immunotherapy of local and distant tumors.